Skip to main content
SleepCited

[Pharmacological Treatment for Restless Legs Syndrome].

Keisuke Suzuki, Tomohiro Tsuchiya, Koichi Hirata
Other Brain and nerve = Shinkei kenkyu no shinpo 2023
PubMed DOI
<\/script>\n
`; }, get iframeSnippet() { const domain = 'sleepcited.com'; const params = 'pmid\u003D37194531'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Abstract

Restless legs syndrome (RLS) is a neurological disorder that causes insomnia and daytime functional disability due to an urge to move the legs usually accompanied by uncomfortable sensations. Non-pharmacologic treatment includes regular sleep habits and exercise. Iron supplementation is indicated for patients with low serum ferritin levels. Antidepressants, antihistaminergics, and dopamine antagonists should be reduced or discontinued because they induce RLS symptoms. Dopamine agonists and alpha 2-delta ligands are the first-line pharmacological treatments for RLS.

En bref

Treatment for restless legs syndrome includes regular sleep habits and exercise, and dopamine agonists and alpha 2-delta ligands are the first-line pharmacological treatments for RLS.

Used In Evidence Reviews

Similar Papers